Inhibitory effect of ethyl acetate extract of the Shaggy Inc Cap medicinal mushroom, Coprinus comatus (Higher Basidiomycetes) fruit bodies on cell growth of human ovarian cancer

International Journal of Medicinal Mushrooms

Volumn 15, Issue 5, 2013, Pages 457-470

  Rouhana Toubi, Amal ^a,b   Wasser, Solomon P ^a,c   Agbarya, Abed ^d   Fares, Fuad ^a,e  

^a UNIVERSITY OF HAIFA   (Israel)

^b ORT BRAUDE COLLEGE   (Israel)

^c M G KHOLODNY INSTITUTE OF BOTANY   (Ukraine)

^d Department of Radiation Oncology   (Israel)

^e CARMEL MEDICAL CENTER   (Israel)

Author keywords

Cell viability; Chromatography; Coprinus comatus; Medicinal mushrooms; Ovarian cancer; Shaggi Inc Cap medicinal mushroom

Indexed keywords

COPRINUS COMATUS EXTRACT; LACTATE DEHYDROGENASE; PLANT EXTRACT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL VIABILITY; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MASS FRAGMENTOGRAPHY; OVARY CANCER;

CELL PROLIFERATION; CELL SURVIVAL; COPRINUS; FEMALE; FRUITING BODIES, FUNGAL; GROWTH INHIBITORS; HUMANS; MYCELIUM; OVARIAN NEOPLASMS; PLANT EXTRACTS; VEGETABLES;

EID: 84886871228     PISSN: 15219437     EISSN: 19404344     Source Type: Journal    
DOI: 10.1615/IntJMedMushr.v15.i5.40     Document Type: Article

References (63)

1. Runnebaum IB, Stickeler E. Epidemiological and mo-lecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol. 2001;127:73-79.
2. Wilson AP. The development of human ovarian epithe-lial tumor cell lines from solid tumors and ascites. In: Pfragner R, Freshney RI, editors. Culture of Human Tu-mor Cells. Hoboken, NJ: Wiley Online Library, 2004, p. 145-178.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10-29.
4. Bast RC, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. J Natl Cancer Inst. 1992;84:556-559.
5. Nnene I, Nieto J, Crow J, Sundaresan M, MacLean A, Perrett C, Hardiman P. Cell cycle and apoptotic proteins in relation to ovarian epithelial morphology. Gynecol Oncol. 2004;92:247-251.
6. Bae SN, Lee YS, Kim MY, Kim JD, Park LO. Antipro-liferative and apoptotic effects of zinc-citrate compound (CIZAR®) on human epithelial ovarian cancer cell line, OVCAR-3. Gynecol Oncol. 2006;103:127-136.
7. Wen WH, Reles A, Runnebaum IB, Sullivan-Halley J, Bernstein L, Jones LA, Press MF. p53 mutations and expression in ovarian cancers: Correlation with overall survival. Int J Gynecol Pathol. 1999;18:29-41.
8. Whittemore AS, Harris R, Itnyre J. The collaborative ovarian cancer group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. invasive epithelial ovarian cancers in white women. Am J Epidemiol. 1992;136:1184-1203.
9. Shu XO, Gao YT, Yuan JM, Ziegler R, Brinton L. Di-etary factors and epithelial ovarian cancer. Br J Cancer. 1989;59:92-96.
10. McCann SE, Freudenheim JL, Marshall JR, Graham S. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. J Nutr. 2003;133:1937-1942.
11. Hanna L. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2006;20:339-362.
12. Risch HA, Jain M, Marrett LD, Howe GR. Dietary fat intake and risk of epithelial ovarian cancer. J Natl Cancer Inst. 1994;86:1409-1415.
13. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the million women study: Cohort study. BMJ. 2007;335:1134-1139.
14. Farrow DC, Weiss NS, Lyon JL, Daling JR. Association of obesity and ovarian cancer in a case-control study. Am J Epidemiol. 1989;129:1300-1304.
15. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer: Case-con-trol study and systematic review (Australia). Cancer Causes Control. 2001;12:855-863.
16. Holzner B, Kemmler G, Meraner V, Maislinger A, Kopp M, Bodner T, Sperner-Unterweger B. Fatigue in ovarian carcinoma patients. Cancer. 2003;97:1564-1572.
17. Kehoe S. Treatments for gynaecological cancers. Best Pract Res Clin Obstet Gynaecol. 2006;20:985-1000.
18. Yusuf R, Duan Z, Lamendola D, Penson R, Seiden M. Paclitaxel resistance: Molecular mechanisms and phar-macologic manipulation. Curr Cancer Drug Targets. 2003;3:1-19.
19. Singh RK, Lange TS, Kim KK, Shaw SK, Brard L. A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells. Gynecol Oncol. 2008;109:240-249.
20. Carlsson M, Strang P, Bjurström C. Treatment modality affects long-term quality of life in gynecological cancer. Anticancer Res. 2000;20:563-568.
21. Lutgendorf SK, Anderson B, Rothrock N, Buller RE, Sood, AK, Sorosky JI. Quality of life and mood in wom-en receiving extensive chemotherapy for gynecologic cancer. Cancer. 2000;89:1402-1411.
22. Holzner B, Kemmler G, Meraner V, Maislinger A, Kopp M, Bodner T, Sperner-Unterweger B. Fatigue in ovarian carcinoma patients. Cancer. 2003;97:1564-1572.
23. Chang Sh-T, Wasser SP. The role of culinary-medicinal mushrooms on human welfare with pyramid model for human health. Int J Med Mushrooms. 2012;14:95-134.
24. Hawksworth DL. Mushrooms: The extent of the unex-plored potential. Int J Med Mushrooms. 2001;3:333-340.
25. Wasser SP. Medicinal mushrooms as a source of antitu-mor and immunomodulating polysaccharides. Appl Mi-crobiol Biotechnol. 2002;60:258-274.
26. Wasser SP. Medicinal mushroom science: history, current status, future trends, and unsolved problems. Int J Med Mushrooms. 2010;12:1-16.
27. Watson RR, Preedy VR. Bioactive foods and extracts: Cancer treatment and prevention. Boca Raton, FL: CRC Press, 2010.
28. Mizuno T. Bioactive biomolecules of mushrooms: Food function and medicinal effect of mushroom fungi. Food Rev Int. 1995;11:5-21.
29. Shamtsyan M, Konusova V, Maksimova Y, Goloshchev A, Panchenko A, Simbirtsev A, Denisova N. Immuno-modulating and anti-tumor action of extracts of several mushrooms. J Biotech. 2004;113:77-83.
30. Petrova RD, Wasser SP, Mahajna JA. Potential role of medicinal mushrooms in breast cancer treatment: Cur-rent knowledge and future perspectives. Int J Med Mush-rooms. 2005;7:141-155.
31. Petrova RD, Mahajna J, Reznick AZ, Wasser SP, Denchev CM, Nevo E. Fungal substances as modulators of NF-κB activation pathway. Mol Biol Rep. 2007;34:145-154.
32. Fujimiya Y, Suzuki Y, Oshiman K, Kobori H, Morigu-chi K, Nakashima H. Katakura R. Selective tumoricidal effect of soluble proteoglucan extracted from the basid-iomycete, Agaricus blazei Murrill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Im-munother. 1998;46:147-159.
33. Gu YH, Belury MA. Selective induction of apoptosis in murine skin carcinoma cells (CH72) by an ethanol ex-tract of Lentinula edodes. Cancer Lett. 2005;220:21-28.
34. Gu YH, Leonard J. In vitro effects on proliferation, apoptosis and colony inhibition in ER-dependent and ER-independent human breast cancer cells by selected mushroom species. Oncol Rep. 2006;15:417-423.
35. Lorenzen K, Anke T. Bsidiomycetes as a source for new bioactive natural products. Curr Org Chem. 1998;2:329-364.
36. Zaidman BZ, Yassin M, Mahajna J, Wasser SP. Medici-nal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol. 2005;67:453-468.
37. Wu JY, Zhang QX, Leung PH. Inhibitory effects of ethyl acetate extract of Cordyceps sinensis mycelium on various cancer cells in culture and B16 melanoma in C57BL/6 mice. Phytomed. 2007;14:43-49.
38. Fang N, Li Q, Yu S, Zhang J, He L, Ronis MJJ, Bad-ger TM. Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms. J Altern Complement Med. 2006;12:125-132.
39. Shimizu Y, Hasumi K, Chen JT, Hirai Y, Nakayama K, Teshima H, Masubuchi K. Successful treatment of a pa-tient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU. Nihon Gan Chiryo Gakkai Shi. 1989;24:647-651. (In Japanese.)
40. Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa J, Karita T. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy: A prospective randomized controlled study. Biotherapy. 1993;6:13-18.
41. Chen JT, Hasumi K, Masubuchi K. Interferon-α, interferon-γ and sizofiran in the adjuvant therapy in ovar-ian cancer - a preliminary trial. Biotherapy. 1992;5:275-280.
42. Chen JT, Hasumi K. Activation of peritoneal macro- phages in patients with gynecological malignancies by sizofiran and recombinant interferon-γ. Biotherapy. 1993;6:189-194.
43. Yun BS, Kang HC, Koshino H, Yu SH, Yoo ID. Suillusin, a unique benzofuran from the mushroom Suillus granula-tus. J Nat Prod. 2001;64:1230-1231.
44. Rouhana-Toubi A, Wasser SP, Fares F. Ethyl acetate ex-tracts of submerged cultured mycelium of higher Basid-iomycetes mushrooms inhibit human ovarian cancer cell growth. Int J Med Mushrooms. 2009;11:29-37.
45. Yilmaz N, Solmaz M, Turkekul I, Elmastas M. Fatty acid composition in some wild edible mushrooms growing in the middle black sea region of Turkey. Food Chem. 2006;99:168-174.
46. Fan JM, Zhang, JS, Tang QJ, Liu YF, Zhang, AQ, Pan YJ. Structural elucidation of a neutral fucogalactan from the mycelium of Coprinus comatus. Carbohydr Res. 2006;341:1130-1134.
47. Zaidman BZ, Wasser SP, Nevo E, Mahajna J. Coprinus comatus and Ganoderma lucidum interfere with andro-gen receptor function in LNCaP prostate cancer cells. Mol Biol Rep. 2008;35:107-117.
48. Lv Y, Han L, Yuan C, Guo J. Comparison of hypogly-cemic activity of trace elements absorbed in fermented mushroom of Coprinus comatus. Biol Trace Elem Res. 2009;131:177-185.
49. Dotan N, Wasser SP, Mahajna J. The culinary-medicinal mushroom Coprinus comatus as a natural antiandrogenic modulator. Integr Cancer Ther. 2011;10:148-159.
50. Cseke LJ, Setzer WN, Vogler B, Kirakosyan A, Kauf-man PB. Traditional, analytical, and preparative separa-tions of natural products. In: Cseke LJ, Kirakosyan A, Kaufman PB, Warber SL, Duke JA, Brielmann HL, edi-tors. Natural Products from Plants. 2 ed. New York: CRC Press, Taylor & Francis Group, 2006, p. 263-317.
51. Um SJ, Lee SY, Kim EJ, Han HS, Koh YM, Hong KJ, Park JS. Antiproliferative mechanism of retinoid deriva-tives in ovarian cancer cells. Cancer Lett. 2001;174:127-134.
52. Van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resis-tance. Int J Biochem Cell Biol. 2010;42:1282-1290.
53. Lv W, Sheng X, Chen T, Xu Q, Xie X. Jaceosidin in-duces apoptosis in human ovary cancer cells through mitochondrial pathway. J Biomed Biotechnol. 2008, Article ID 394802.
54. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri E, Baehrecke E, Green D. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 2008;16:3-11.
55. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, Kroemer G. Cell death modalities: classifi-cation and pathophysiological implications. Cell Death Differ. 2007;14:1237-1243.
56. Gringauz A. Introduction to Medicinal Chemistry: How Drugs Act and Why. Weinheim, Germany: Wiley-VCH, 1977.
57. 2 induction of the NF-κB pathway through inhibition of IκBα phosphor-ylation in MCF7 breast cancer cells. Int J Med Mush-rooms. 2011;13:19-25.
58. Tang W, Gu T, Zhong JJ. Separation of targeted ganod-eric acids from Ganoderma lucidum by reversed phase liquid chromatography with ultraviolet and mass spec-trometry detections. Biochem Eng J. 2006;32:205-210.
59. Wang XM, Yang M, Guan SH, Liu RX, Xia JM, Bi KS, Guo DA. Quantitative determination of six major tri-terpenoids in Ganoderma lucidum and related species by high performance liquid chromatography. J Pharm Biomed Anal. 2006;41:838-844.
60. Zhang Y, Mills GL, Nair MG. Cyclooxygenase inhibi-tory and antioxidant compounds from the mycelia of the edible mushroom Grifola frondosa. J Agric Food Chem. 2002;50:7581-7585.
61. Li B, Lu F, Suo X, Nan H, Li B. Antioxidant properties of cap and stipe from Coprinus comatus. Molecules. 2010;15:1473-1486.
62. Malek SNA, Shin SK, Wahab NA, Yaacob H. Cytotoxic components of Pereskia bleo (Kunth) DC.(Cactaceae) leaves. Molecules. 2009;14:1713-1724.
63. Mazurkiewicz W, Rydel K, Pogocki D, Kinga M, Lang-ner LE, Rzeski W. Separation of an aqueous extract Ino-notus obliquus (Chaga). A novel look at the efficiency of its influence on proliferation of A549 human lung carci-noma cells. Acta Pol Pharm. 2010;67:397-406.